Ambry will participate in NorthShore’s genomic health initiative, performing whole exome sequencing on 10,000 patients enrolled in the research project. Ambry will compile the sequenced data and the patient’s EMR information, which may provide insights into the link between genetic variation and disease.
“Preventing and managing disease through scientific excellence and high-quality care is the cornerstone of this partnership,” said Aaron Elliott, PhD, CEO of Ambry. “NorthShore and Ambry share the same patient-first philosophy and focus on scientific innovation to improve the future of healthcare.”
More articles on data analytics & precision medicine:
23andMe to expand with $200M in latest funding round
UC Davis to use precision medicine in pancreatic cancer care
Global genomic data platform WuXi NextCODE raises $240M
